Strong Funding Backing SpliceBio has raised a substantial $135 million in Series B financing from prominent investors like EQT, Sanofi, Roche Venture Fund, and others, indicating significant growth potential and a strong financial foundation to accelerate sales of innovative gene therapies.
Innovative Protein Splicing Platform The company's proprietary platform based on protein splicing technology offers unique therapeutic solutions, presenting opportunities to partner or provide supplemental services in cutting-edge gene therapy development and delivery systems.
Active Collaborations Partnerships with established players such as Spark Therapeutics and collaborations with industry leaders like Sanofi position SpliceBio as a strategic partner, opening doors for joint ventures and co-development opportunities.
Pipeline Expansion With ongoing development efforts in Stargardt disease and other splicing-regulated Meds, there is potential to expand sales by supporting clinical trial services, regulatory filings, and eventual commercialization of these novel therapies.
Growing Market Presence Located in Barcelona with a focused biotech niche and substantial investor interest, SpliceBio offers opportunities to engage with emerging markets in gene therapy, positioning solutions for future market expansion and targeted sales initiatives.
$100M$250M
$1B$10B
$1M$10M
$50M$100M
$10M$25M
$250M$500M
$250M$500M
$500M$1B
$50M$100M
$100M$250MSplice Bio uses 8 technology products and services including RSS, CookieYes, Underscore.js, and more. Explore Splice Bio's tech stack below.
| Splice Bio Email Formats | Percentage |
| First.Last@splice.bio | 46% |
| First.Middle@splice.bio | 4% |
| First.Last@splice.bio | 46% |
| First.Middle@splice.bio | 4% |
Biotechnology ResearchCatalonia, Spain51-200 Employees
SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.
Company Overview
Funding & FinancialsSplice Bio has raised a total of $135M of funding over 4 rounds. Their latest funding round was raised on Jun 11, 2025 in the amount of $135M.
Splice Bio's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsSplice Bio has raised a total of $135M of funding over 4 rounds. Their latest funding round was raised on Jun 11, 2025 in the amount of $135M.
Splice Bio's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com